Bromfed Dosing Guidelines
For adults and children ≥12 years: 10 mL every 4 hours; children 6-11 years: 5 mL every 4 hours; children 2-5 years: 2.5 mL every 4 hours; and for infants 6 months to <2 years: physician-established dosing only—however, avoid use entirely in children <6 years due to lack of efficacy and significant safety concerns. 1
Age-Based Dosing Algorithm
Adults and Adolescents (≥12 years)
- Dose: 10 mL (2 teaspoonfuls) every 4 hours
- Maximum: 6 doses per 24 hours 1
School-Age Children (6 to <12 years)
- Dose: 5 mL (1 teaspoonful) every 4 hours
- Maximum: 6 doses per 24 hours 1
Young Children (2 to <6 years)
- FDA-labeled dose: 2.5 mL (½ teaspoonful) every 4 hours 1
- Critical caveat: Despite FDA labeling, avoid use in this age group based on guideline recommendations (see safety section below)
Infants (6 months to <2 years)
- FDA label states: "Dosage to be established by a physician" 1
- Strong recommendation: Do not use—no established efficacy and significant mortality risk (see safety section)
Critical Safety Considerations
Children Under 6 Years: Strong Evidence Against Use
The most important clinical decision point is recognizing that OTC cough and cold medications should generally be avoided in all children below 6 years of age due to lack of proven efficacy and potential toxicity. 2
The evidence supporting this recommendation is compelling:
Mortality data: Between 1969-2006, there were 54 fatalities associated with decongestants (pseudoephedrine, phenylephrine, ephedrine) in children ≤6 years, with 43 deaths occurring in infants <1 year 2
Antihistamine fatalities: During the same period, 69 deaths were associated with antihistamines including brompheniramine (9 fatalities), with 41 deaths in children <2 years 2
Common causes: Drug overdose and toxicity resulted from using multiple cold/cough products simultaneously, medication errors, accidental exposures, and intentional overdose 2
Lack of efficacy: Controlled trials demonstrate that antihistamine-decongestant combination products are not effective for upper respiratory tract infection symptoms in young children 2
FDA and Industry Response
In October 2007, major manufacturers (Wyeth, Novartis, Prestige Brands, Johnson & Johnson) voluntarily removed cough and cold medications for children <2 years from the OTC market. The FDA's advisory committees recommended against use in children <6 years 2.
Dosing Intervals and Maximum Limits
- Frequency: Every 4 hours as needed
- Absolute maximum: Do not exceed 6 doses in 24 hours across all age groups 1
- Duration: Keep treatment as short as possible for acute conditions
Component-Specific Considerations
Brompheniramine Pharmacology in Children
Research shows brompheniramine in children (mean age 9.5 years) has:
- Peak concentration at 3.2 hours
- Terminal half-life of 12.4 hours
- Duration of H1-blockade: 30 hours for wheals, suggesting once or twice daily dosing may be more appropriate than every 4 hours 3
This pharmacokinetic data suggests the every-4-hour dosing may lead to drug accumulation in children.
Dextromethorphan Toxicity Thresholds
- Monitoring threshold: Ingestions of 5-7.5 mg/kg require poison center follow-up every 2 hours for 4 hours 4
- Emergency department referral: Ingestions >7.5 mg/kg 4
- Dose-response in children: Some evidence suggests 0.5 mg/kg may balance efficacy with adverse event avoidance 5
Pseudoephedrine Considerations
The standalone pseudoephedrine FDA label explicitly states "do not use this product in children under 6 years of age" 6, which reinforces the recommendation against Bromfed use in young children.
Common Pitfalls to Avoid
Multiple product use: Parents often administer multiple OTC products simultaneously, leading to overdose—verify no other medications containing these ingredients are being used
Age vs. weight dosing: The FDA label uses age-based dosing, but this creates substantial variability in actual drug exposure per kilogram 5
Confusion with prescription status: While Bromfed may be available, availability does not equal appropriateness for young children
Duration of use: Even when used in appropriate age groups, limit duration to the shortest time necessary for symptom control
Alternative Approaches for Young Children
For children <6 years with rhinitis symptoms, consider:
- Second-generation antihistamines (cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine) have demonstrated good safety profiles and tolerability in young children 2
- These agents are preferred over first-generation antihistamines like brompheniramine